MAP raises $43.5 million PIPE as Levodex nears filing
This article was originally published in Scrip
Executive Summary
MAP Pharmaceuticals is raising $43.5 million in a registered direct offering of common stock to fund the development of its Levadex inhaled therapy for migraine and other drugs.